Arkadios Wealth Advisors Acquires 6,734 Shares of GSK PLC Sponsored ADR $GSK

Arkadios Wealth Advisors boosted its holdings in GSK PLC Sponsored ADR (NYSE:GSK) by 10.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 68,760 shares of the pharmaceutical company’s stock after purchasing an additional 6,734 shares during the period. Arkadios Wealth Advisors’ holdings in GSK were worth $2,640,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. Ethic Inc. lifted its stake in GSK by 13.1% in the second quarter. Ethic Inc. now owns 159,588 shares of the pharmaceutical company’s stock worth $6,157,000 after purchasing an additional 18,499 shares during the last quarter. Cullen Frost Bankers Inc. lifted its stake in GSK by 4.7% in the second quarter. Cullen Frost Bankers Inc. now owns 375,481 shares of the pharmaceutical company’s stock worth $14,418,000 after purchasing an additional 16,999 shares during the last quarter. Yousif Capital Management LLC lifted its stake in GSK by 7.9% in the second quarter. Yousif Capital Management LLC now owns 25,681 shares of the pharmaceutical company’s stock worth $986,000 after purchasing an additional 1,875 shares during the last quarter. Trust Co. of Toledo NA OH lifted its stake in GSK by 2.7% in the second quarter. Trust Co. of Toledo NA OH now owns 30,805 shares of the pharmaceutical company’s stock worth $1,183,000 after purchasing an additional 797 shares during the last quarter. Finally, NBT Bank N A NY lifted its stake in GSK by 3.2% in the second quarter. NBT Bank N A NY now owns 14,765 shares of the pharmaceutical company’s stock worth $567,000 after purchasing an additional 452 shares during the last quarter. 15.74% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Jefferies Financial Group reissued a “buy” rating on shares of GSK in a research note on Monday. Cfra set a $53.00 target price on shares of GSK in a report on Thursday. Weiss Ratings reiterated a “hold (c)” rating on shares of GSK in a report on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, September 5th. One research analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, GSK currently has a consensus rating of “Hold” and an average target price of $42.58.

GSK Stock Performance

GSK stock opened at $47.06 on Friday. GSK PLC Sponsored ADR has a 1-year low of $31.72 and a 1-year high of $47.16. The firm has a market cap of $95.66 billion, a P/E ratio of 13.29, a P/E/G ratio of 1.90 and a beta of 0.53. The firm has a 50-day moving average of $41.96 and a 200-day moving average of $39.64. The company has a current ratio of 0.87, a quick ratio of 0.57 and a debt-to-equity ratio of 1.07.

GSK (NYSE:GSK) last released its quarterly earnings results on Wednesday, October 29th. The pharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.22. GSK had a net margin of 17.16% and a return on equity of 51.07%. The company had revenue of $11.35 billion during the quarter, compared to the consensus estimate of $8.21 billion. During the same period in the prior year, the firm earned $0.50 earnings per share. GSK’s revenue was up 6.7% on a year-over-year basis. GSK has set its FY 2025 guidance at 4.730-4.810 EPS. Sell-side analysts expect that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.

GSK Cuts Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 8th. Investors of record on Friday, November 14th will be paid a $0.4171 dividend. This represents a $1.67 dividend on an annualized basis and a yield of 3.5%. The ex-dividend date of this dividend is Friday, November 14th. GSK’s dividend payout ratio is presently 47.74%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.